We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
+9.45%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$359M
AUM Growth
–
Cap. Flow
+$346M
Cap. Flow
% of AUM
96.43%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$28.5M |
| 2 |
Pfizer
PFE
|
+$21.5M |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$16M |
| 4 |
Merck
MRK
|
+$13.4M |
| 5 |
SHPG
Shire pic
SHPG
|
+$8.54M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.19% |
| 2 | Consumer Discretionary | 4.33% |
| 3 | Technology | 3.68% |
| 4 | Industrials | 3.52% |
| 5 | Consumer Staples | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Johnson & Johnson
JNJ
$618B
| $32.1M | 8.93% |
+350,000
| New | +$32.3M |
|
|
2
GSK
GSK
$104B
| $29.4M | 8.18% |
+440,000
| New | +$28.5M |
|
|
3
Pfizer
PFE
$143B
| $21.5M | 5.99% |
+740,431
| New | +$21.5M |
|
|
4
CALL
Pfizer
PFE
$143B
| $20M | 5.56% |
+687,313
| New | +$20M |
|
|
5
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
| $16.7M | 4.65% |
+869,004
| New | +$16M |
|
|
6
Merck
MRK
$322B
| $14M | 3.9% |
+293,440
| New | +$13.4M |
|
|
7
CALL
Merck
MRK
$322B
| $10M | 2.79% |
+209,600
| New | +$9.58M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $9.18M | 2.56% |
+65,000
| New | +$8.54M |
|
9
PUT
Gilead Sciences
GILD
$162B
| $9.02M | 2.51% |
+120,000
| New | +$8.36M |
|
10
Amgen
AMGN
$208B
| $7.99M | 2.23% |
+70,000
| New | +$7.96M |
|
11
iShares Russell 2000 ETF
IWM
$79.8B
| $7.75M | 2.16% |
+67,209
| New | +$7.42M |
|
12
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $7.54M | 2.1% |
+136,023
| New | +$7.27M |
|
13
Invesco QQQ Trust
QQQ
$453B
| $7.1M | 1.98% |
+80,700
| New | +$6.72M |
|
|
14
Gilead Sciences
GILD
$162B
| $7.06M | 1.97% |
+94,000
| New | +$6.55M |
|
15
Incyte
INCY
$24.2B
| $6.58M | 1.83% |
+130,000
| New | +$5.66M |
|
16
Teva Pharmaceuticals
TEVA
$40.8B
| $6.01M | 1.67% |
+150,000
| New | +$5.91M |
|
17
State Street Industrial Select Sector SPDR ETF
XLI
$32.8B
| $4.95M | 1.38% |
+94,623
| New | +$4.65M |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.9M | 1.36% |
+122,800
| New | +$5.01M |
|
19
TJX Companies
TJX
$174B
| $4.16M | 1.16% |
+130,432
| New | +$3.95M |
|
|
20
CALL
Teva Pharmaceuticals
TEVA
$40.8B
| $4.01M | 1.12% |
+100,000
| New | +$3.94M |
|
21
Ironwood Pharmaceuticals
IRWD
$696M
| $4M | 1.12% |
+411,930
| New | +$3.7M |
|
|
NPSP
22
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $3.89M | 1.08% |
+128,000
| New | +$3.53M |
|
23
Check Point Software Technologies
CHKP
$13B
| $3.57M | 0.99% |
+55,353
| New | +$3.33M |
|
24
Colgate-Palmolive
CL
$73.1B
| $3.48M | 0.97% |
+53,299
| New | +$3.41M |
|
25
Biogen
BIIB
$30B
| $3.36M | 0.94% |
+12,000
| New | +$3.1M |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Sphera Funds Management, which disclosed 96 positions worth $359M. Its ten largest holdings account for 47% of the portfolio.
Its largest position is GSK: 440,000 shares worth $29.4M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, followed by Consumer Discretionary and Technology.
- Sphera Funds Management's largest Q4 2013 buy was GSK: 440,000 shares worth $29.4M.
- Sphera Funds Management's ten largest holdings make up 47% of its $359M portfolio in Q4 2013.
- Sphera Funds Management disclosed 96 positions in Q4 2013, its first 13F filing on record.
Based on Sphera Funds Management's 13F filing for Q4 2013, filed 13 Feb 2014.